Datapoint: AbbVie Completes ImmunoGen Deal

AbbVie this week closed its $10.1 billion acquisition of ImmunoGen, a Waltham, Mass.-based biotech that specializes in cancer-fighting antibody-drug conjugates (ADCs). The deal nets AbbVie Elahere (mirvetuximab soravtansine-gynx), ImmunoGen’s ovarian cancer therapy — the only ADC in the ovarian cancer market basket. The drug, which scored an FDA nod in 2022, is approved to treat folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients that have already received one to three prior systemic therapies. AbbVie will work on making Elahere an earlier line of treatment and expanding its patient pool. For the treatment of ovarian cancer, Elahere currently holds covered or better status for 58% of all insured lives under the medical benefit. Evaluate Pharma projects global sales will reach $1.2 billion by 2028.

From Evaluate Pharma and MMIT Analytics, as of 2/14/24

0

0

0 Comments

0

0

• Datapoint